Compare Godaddy Inc (GDDY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Godaddy Inc trades at $95.33 (market cap $12.09B), while Regeneron Pharmaceuticals Inc trades at $676.86 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.8× Godaddy Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| GDDY | REGN | |
|---|---|---|
Market Cap | $12.09B | $69.66B |
Sector | Technology | Health |
52-Week High | $169.40 | $812.27 |
52-Week Low | $75.07 | $542.52 |
Enterprise Value | $14.67B | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $94.12, up 3.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 results due July 30, 2026. Fundamentals show robust profitability with a 17.32% net margin and 63.77% gross margin, though revenue growth is moderating. Analyst consensus is bullish with a $123 price target, but legal investigations pose sentiment risks.
Outlook remains positive given earnings momentum and high analyst buy ratings, but investors face near-term volatility from legal overhangs and elevated valuation multiples. The stock offers upside to consensus targets if execution continues, yet legal and competitive pressures require monitoring for sustained growth.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
